Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 7/20 | 0.44 |
| ▸ | NOS1 | P29475 | 6/20 | 0.44 |
| ▸ | NOS3 | P29474 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | PAK1 | Q13153 | 4/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | KMT5B | Q4FZB7 | 1/20 | 0.36 |
| ▸ | KMT5C | Q86Y97 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10137672 | 0.83 | ALDH1A1 (0.54) | NOS2NOS1NOS3ALDH1A1BTK | |
| SCHEMBL3063816 | 0.82 | ALDH1A1 (0.46) | NOS2NOS1KMT2AMEN1ALDH1A1 | |
| SCHEMBL304702 | 0.81 | HCAR3 (0.39) | NOS2NOS1NOS3KMT2AKDM4E | |
| SCHEMBL304703 | 0.81 | HCAR3 (0.39) | NOS2NOS1NOS3KMT2AKDM4E | |
| Ammonia Solution, Strong SCHEMBL28775699 | 0.81 | ALDH1A1 (0.45) | NOS2NOS1KMT2AMEN1ALDH1A1 | |
| SCHEMBL303845 | 0.78 | PAK1 (0.47) | ALDH1A1PAK1BTK | |
| SCHEMBL19917166 | 0.78 | KMT5B (0.52) | KMT2AKDM4EMEN1ALDH1A1KMT5B | |
| SCHEMBL788473 | 0.76 | SHMT2 (0.44) | NOS2NOS1NOS3KMT2AKDM4E | |
| SCHEMBL28076726 | 0.74 | JAK3 (0.40) | NOS2NOS1KMT2AMEN1JAK3 | |
| SCHEMBL28076725 | 0.74 | JAK3 (0.40) | NOS2NOS1KMT2AMEN1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476283-B2 | [6,5]—bicyclic GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-02 | — | — | US | disclosed |
| EP-2152707-B1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20120077826-A1 | [6,5] - BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-29 | — | — | US | disclosed |
| US-8093257-B2 | [6,5]-bicyclic GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2152707-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | Bristol-Myers Squibb Company (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20090018055-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-15 | — | — | US | disclosed |
| WO-2008137436-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018055-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR139, GPR4 | NOS2 2375/4885NOS1 2062/4885NOS3 2513/4885 |
| US-20120077826-A1 | [6,5] - BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR139, GPR4 | NOS2 2375/4885NOS1 2062/4885NOS3 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.